PLMJ advises GammaDelta Therapeutics on acquisition of Lymphact

PLMJ advised GammaDelta Therapeutics, Limited, a British company that specialises in gamma delta T cells, on its acquisition of Lymphact – Lymphocyte Activation Technologies, S.A.

The PLMJ Private Equity team handling this operation was made up of partner Barbara Godinho Correia, and by associate, Pedro Gaspar da Silva. These two lawyers were assisted by the PLMJ Intellectual Property team, made up of partner Manuel Lopes Rocha, and associate Lourenço Noronha dos Santos. Lymphact is a bio-pharma start-up that focuses on developing personalised medical treatment, and it has developed a technological platform that can manage cellular immunological therapies – DOT-Cells®.

The potential synergies arising from the position will allow Gamma Delta Therapeutics to develop the DOT-Cells® technologies and the gamma delta (γδ) T cells platform, to boost the availability of new therapies for oncological diseases.

The PLMJ Private Equity and M&A teams have advised on the most important deals in the Portuguese market and this fact has been recognised by Transnational Track Record (TTR). In its 2017 ranking, TTR named PLMJ the Portuguese leader in M&A and private equity, not only in the number of lawyers recognised, but also in the number of transactions.